TPM3 and colorectal carcinoma: Specifically, we tested the activity of zurletrectinib against two primary colorectal cancer (CRC) cell lines harboring a LMNA-NTRK1 fusion (IRC-I-XL [14]), or a TPM3-NTRK1 fusion (Kor1 [24]).